Stocklytics Platform
Asset logo for symbol RLMD
Relmada Therapeutics
RLMD53
$0.36arrow_drop_up2.92%$0.01
Penny Stock
Asset logo for symbol RLMD
RLMD53

$0.36

arrow_drop_up2.92%

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Relmada Therapeutics (RLMD) Stocklytics Forecast

According to market analysts, Relmada Therapeutics Inc (RLMD) is expected to experience significant growth in the coming years. With a focus on developing innovative therapies for treating central nervous system (CNS) disorders, RLMD has positioned itself as a key player in the biopharmaceutical industry.
Experts predict that RLMD stock price will continue to rise in the near future due to several factors. First and foremost, the company's robust pipeline of potential treatments for various CNS disorders is seen as a major catalyst for growth. These include therapies for depression, schizophrenia, and neuropathic pain, among others.
add Relmada Therapeutics to watchlist

Keep an eye on Relmada Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Relmada Therapeutics (RLMD) stock?

Analysts have set a target price of $41.57 for Relmada Therapeutics (RLMD), based on forecasts from 7 analysts. The predicted price range extends from a high of $81 to a low of $8. This represents a potential increase of up to 22.22K% and a decrease of 2.1K% from the current price of $0.36. These forecasts are as of 2019 Dec 16.
help

What are the analyst ratings for Relmada Therapeutics (RLMD) stock?

The analyst ratings for Relmada Therapeutics (RLMD) are distributed as follows: 3 analysts recommend buying, 0 have a neutral stance, and 1 suggest selling. The prevailing sentiment among the total of 4 analysts leans towards a buy rating. These ratings indicate the general sentiment among the analysts covering Relmada Therapeutics .
help

What is the AI price prediction for Relmada Therapeutics (RLMD) stock?

At present, there is no AI or machine-learning-based price prediction available for Relmada Therapeutics (RLMD) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level